This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

FAST as a Treatment for Obstructive Sleep Apnea (FAST)

This study has been terminated.
(Slow enrollment)
Sponsor:
Information provided by (Responsible Party):
Siesta Medical, Inc.
ClinicalTrials.gov Identifier:
NCT01611779
First received: May 29, 2012
Last updated: January 10, 2017
Last verified: January 2017
May 29, 2012
January 10, 2017
May 2012
June 2013   (Final data collection date for primary outcome measure)
  • Place the Implant and Stabilize the Tongue [ Time Frame: Up to 7 weeks after the procedure ]
    Ability to place the implant and stabilize the tongue
  • Number of Participants Experiencing Complications [ Time Frame: 3 months ]
    Patient will be examined by the investigator at each of the follow-up visits for the presence of any untoward or unintended response to the device.
  • Ability to place the implant and stabilize the tongue [ Time Frame: Up to 7 weeks after the procedure ]
    Ability to place the implant and stibilize the tongue
  • Complications [ Time Frame: 3 months ]
    Evaluate safety of the device
Complete list of historical versions of study NCT01611779 on ClinicalTrials.gov Archive Site
  • Apnea Hypopnea Index [ Time Frame: Baseline, 3, and 12 months ]
    0 to >30/hour (high value represents worse outcome)
  • Functional Outcomes and Sleep Questionnaire (FOSQ) [ Time Frame: Baseline, 1, 3, 12 months ]
    Questionnaire: 0 to 120 (high value represents better outcome)
  • Snoring Scale (VAS) [ Time Frame: Baseline, 1 week; 1 month, 3 months, 12 months ]
    0 to 10 (high value represents worse outcome)
  • Epworth Sleeping Scale (ESS) [ Time Frame: Baseline, 1, 3, 12 months ]
    0 to 24 (high value represents worse outcome)
  • Apnea Hypopnea Index [ Time Frame: 3 and 12 months ]
    0 to >30/hour (high value represents worse outcome)
  • Functional Outcomes and Sleep Questionnaire (FOSQ) [ Time Frame: 1, 3, 12 month ]
    0 to 120 (high value represents better outcome)
  • Snoring Scale (VAS) [ Time Frame: 1 week; 1, 3, 12 months ]
    0 to 10 (high value represents worse outcome)
  • Epworth Sleeping Scale (ESS) [ Time Frame: 1, 3, 12 months ]
    0 to 24 (high value represents worse outcome)
Not Provided
Not Provided
 
FAST as a Treatment for Obstructive Sleep Apnea
Functional Advancement and Suspension of the Tongue (FAST) as a Treatment for Obstructive Sleep Apnea
The objective of this study is to assess the feasibility and safety of tongue suspension using the Siesta Medical Encore Tongue Suspension System for the treatment of obstructive sleep apnea (OSA).

Obstructive sleep apnea (OSA) has become a major health problem in the United States. With prevalence in middle-aged adults of 2-4% of the population, untreated OSA has been implicated in increased risk for cardiovascular disease, including hypertension and heart failure.

The first and most common treatment for OSA is continuous positive airway pressure (CPAP) treatment, utilized by an estimated 3 million Americans. CPAP is effective in reducing apnea-hypopnea index (AHI) is used properly. However, the nasal mask required for CPAP during sleep leads to poor acceptance and compliance rates. Published studies on CPAP have shown that only 58-8-% of patient accept CPAP therapy and further 65-90% of these patients exhibit long-term compliance with CPAP.

It is widely accepted that the region behind the tongue is a major site of collapse during obstructive sleep apnea. In fact there are many surgical procedures performed currently to address tongue based collapse. These include RF ablation of the tongue base, genioglossus advancement, hyoid suspension, maxillomandibular advancement, and tongue base suspension.

The current study is designed to evaluate the feasibility of tongue stabilization, and assess safety and treatment of the tongue stabilization.

Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Obstructive Sleep Apnea
Device: Encore Tongue Suspension System
The primary components of the Encore Tongue Suspension System consist of a suture passer, suspension line and bone screw.
Other Names:
  • Tongue suspension
  • FG0002
Experimental: Tongue suspension
Tongue-based suspension
Intervention: Device: Encore Tongue Suspension System
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
5
June 2013
June 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Documented diagnosis of moderate obstructive sleep apnea (AHI 5-30/hour) measured within 12 months prior to the planned procedure
  • Age >/= 20 and >/= 65
  • Body Mass Index ,/= 32 (kg/m^2)
  • Patient offered CPAP and has refused of failed to continue CPAP treatment or is not compliant with CPAP
  • Signed informed consent to participate in this study

Exclusion Criteria:

  • Prior OSA surgery
  • Active systemic infection
  • Allergy to any medication used during implantation
  • Previous history of neck or upper respiratory tract
  • Significant dysphagia or speech disorder

Anatomical

  • Identified obvious palatal stenosis
  • Enlarged tonsils (3+)
  • Anatomy unable to accommodate the implant

Other

  • Other medical, social, or psychological problems that , in the opinion of the investigator, precludes the patient from receiving this treatment and the procedures and evaluations pre- and post-treatment
  • Enrollment in another pharmacological or medical device study that may effect or bias the results of this clinical study
  • Unable and/or not willing to comply with treatment follow-up requirements
  • Pregnancy (Female subjects of childbearing potential must have a negative pregnancy test prior to enrollment
Sexes Eligible for Study: All
20 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01611779
2011
No
Not Provided
Plan to Share IPD: No
Siesta Medical, Inc.
Siesta Medical, Inc.
Not Provided
Study Director: Andrew Goldberg, MD University of California, San Francisco
Siesta Medical, Inc.
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP